XNK receives certificate of GMP compliance of a manufacturer from the Medical Products Agency

XNK Therapeutics today announced that it has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for its planned clinical studies.

“We are very happy to receive this license. It is an important milestone for XNK, and we are now well positioned for significant value creation with three to four potential phase I/II readouts in our pipeline over the coming three years. The in-house GMP facility provides us with valuable capacity, flexibility and control over our clinical manufacturing which brings competitive advantages going forward. In addition, the close collaboration and proximity between manufacturing and research & innovation ensures efficient process development and organizational learning,” said Johan Liwing, CEO, XNK Therapeutics.

The building phase of the company’s new GMP clean room facility was completed in September 2022. The GMP facility comprises approximately 350 square meters and is located at XNK in the Novum Research Park, co-located with the Karolinska Institutet and the Karolinska University Hospital in Huddinge, Sweden.

“I am proud of the team which has worked hard over the past 18 months to build and validate our new GMP facility and a regulatory compliant Pharmaceutical Quality System. This will enable us of aseptic production of ATMPs for future clinical trials. This is an important step in the company’s ambitious growth plan to enable further larger clinical trials with our natural killer cell-based therapies,” said Linda Brink, Head of QA at XNK Therapeutics.

Stockholm region’s only GameTech hub is being built in Flemingsberg

In September this year, Press Start took the next step in developing the Stockholm region’s GameTech ecosystem. Since then, the community has continued to grow, more studios have joined, and work on the next major initiative has gained momentum. So, what has happened so far, and what comes next?

CSIB: New interdisciplinary center brings research together to tackle future infectious threats

Center for Systems Infection Biology (CSIB) was recently inaugurated at Campus Flemingsberg. The new interdisciplinary initiative brings together research, advanced infrastructure and expertise to deepen the understanding of infectious diseases and accelerate the path from research to clinical application. We met with Director Ujjwal Neogi and Co-director Iva Filipovic to talk about the center’s goals, its strong focus on collaboration, and its ambition to contribute to pandemic preparedness.

Vecura – 30 Years Dedicated to the Medicine of the Future

In Flemingsberg, pioneers have helped shape the medicine of the future since 1996. This year, the manufacturing unit Vecura celebrates 30 years of supporting the development of cell and gene therapies – advanced therapies that enable more personalized treatments. We spoke with Pontus Blomberg, strategic advisor and former Director of Operations, who has helped build one of Sweden’s leading laboratories in the field.

2023-06-22T12:09:14+02:00
Go to Top